Inherited thrombophilia: Impact on human reproduction

American Journal of Reproductive Immunology

Volumn 50, Issue 1, 2003, Pages 20-32

  Buchholz, Tina ^a   Thaler, Christian J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Fibrinolysis; Hemostasis; Placental perfusion; Pregnancy

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTITHROMBIN III; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 5; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; PROTHROMBIN;

BLOOD CLOTTING; DISEASE COURSE; DISEASE PREDISPOSITION; FEMALE; FIBRINOLYSIS; GENETIC DISORDER; GENETIC VARIABILITY; HEMOSTASIS; HUMAN; INTRAUTERINE GROWTH RETARDATION; PLACENTA PERFUSION; PREECLAMPSIA; PREGNANCY; PREGNANCY DISORDER; PRIORITY JOURNAL; RECURRENT DISEASE; REPRODUCTION; REVIEW; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STILLBIRTH; THROMBOPHILIA; TWIN PREGNANCY;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; FEMALE; FIBRINOLYSIS; HUMANS; POLYMORPHISM, GENETIC; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; REPRODUCTION; THROMBOPHILIA;

EID: 0037484301     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0897.2003.00049.x     Document Type: Review

References (105)

1. Hiller E, Pihusch R: Thrombophilia caused by congenital disorders of blood coagulation. Semin Thromb Hemost 1998; 116:26-28, 30, 32.
2. Bonnar J, Green R, Norris L: Inherited thrombophilia and pregnancy: The obstetrics perspective. Semin Thromb Hemost 1998; 24 Suppl. 1:49-53.
3. Marz W, Nauck M, Wieland H: The molecular mechanisms of inherited thrombophilia. Z Kardiol 2000; 89:575-586.
4. Greer IA: The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med 2000; 342:424-425.
5. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID: Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79:1166-1170.
6. Eldor A: Thrombophilia, thrombosis and pregnancy. Thromb Haemost 2001; 86:104-111.
7. Mousa HA, Alfirevic Z: Thrombophilia and adverse pregnancy outcome. Croat Med J 2001; 42:135-145.
8. Kupferminc MJ, Fait G, Many A, Gordon D, Eldor A, Lessing JB: Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol 2000; 96:45-49.
9. Brenner B, Mandel H, Lanir N, Younis J, Rothbart H, Ohel G et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997; 97:551-554.
10. Brenner B: Inherited thrombophilia and pregnancy loss. Thromb Haemost 1999; 82:634-640.
11. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340:9-13.
12. Fatini C, Gensini F, Battaglini B, Prisco D, Cellai AP, Fedi S et al. Angiotensin-converting enzyme DD genotype, angiotensin type 1 receptor CC genotype, and hyperhomocysteinemia increase first-trimester fetal-loss susceptibility. Blood Coagul Fibrinolysis 2000; 11:657-662.
13. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK: Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol 1989; 161:1200-1204.
14. Salafia CM, Minior VK, Lopez-Zeno JA, Whittington SS, Pezzullo JC, Vintzileos AM: Relationship between placental histologic features and umbilical cord blood gases in preterm gestations. Am J Obstet Gynecol 1995; 173:1058-1064.
15. Robertson WB, Brosens I, Landells WN: Abnormal placentation. Obstet Gynecol Annu 1985; 14:411-426.
16. Hunter AG: A pilot study of the possible role of familial defects in anticoagulation as a cause for terminal limb reduction malformations. Clin Genet 2000; 57:197-204.
17. Gopel W, Ludwig M, Junge AK, Kohlmann T, Diedrich K, Moller J: Selection pressure for the factor-V-Leiden mutation and embryo implantation. Lancet 2001; 358:1238-1239.
18. Shafer JA, Higgins DL: Human fibrinogen. Crit Rev Clin Lab Sci 1988; 26:1-41.
19. Dahlback B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90:1004-1008.
20. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, De Ronde H et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369:64-67.
21. Blumenfeld Z, Brenner B: Thrombophilia-associated pregnancy wastage. Fertil Steril 1999; 72:765-774.
22. Koster T, Rosendaal FR, De Ronde H, Briet E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342:1503-1506.
23. Dahlback B, Zoller B, Hillarp A: Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis. Haemostasis 1996; 26 Suppl 4:301-314.
24. Moland L, Sandset PM: Activated protein C resistance - A recently discovered hereditary thrombophilia Tidsskr Nor Laegeforen 1998; 118:3590-3595.
25. De Stefano V, Chiusolo P, Paciaroni K, Leone G: Epidemiology of factor V Leiden: Clinical implications. Semin Thromb Hemost 1998; 24:367-379.
26. Hashimoto K, Shizusawa Y, Shimoya K, Ohashi K, Shimizu T, Azuma C et al. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod 1999; 14:1872-1874.
27. Chrobak L, Dulicek P: Thrombophilic states. Vnitr Lek 1998; 44:481-486.
28. Lane DA, Grant PJ: Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 2000; 95:1517-1532.
29. Rosing J, Bakker HM, Thomassen MC, Hemker HC, Tans G: Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993; 268:21,130-21,136.
30. Castoldi E, Simioni P, Kalafatis M, Lunghi B, Tormene D, Girelli D et al. Combinations of 4 mutations (FV R506Q, H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. Blood 2000; 96:1443-1448.
31. Akar N, Yilmaz E, Akar E, Avcu F, Yalcin A, Cin S: Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691 G-A. Thromb Res 2000; 97:227-230.
32. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343:1015-1018.
33. Dizon-Townson DS, Kinney S, Branch DW, Ward K: The factor V Leiden mutation is not a common cause of recurrent miscarriage. J Reprod Immunol 1997; 34:217-223.
34. Grandone E, Margaglione M, Colaizzo D, D'Addedda M, Cappucci G, Vecchione G et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77:822-824.
35. Ridker PM, Miletich JP, Buring JE, Ariyo AA, Price DT, Manson JE et al. Factor IV Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med 1998; 128:1000-1003.
36. Tormene D, Simioni P, Prandoni P, Luni S, Innella B, Sabbio P et al. The risk of fetal loss in family members of prbands with factor V Leiden mutations. Thromb Haemost 1999; 82:1237-1239.
37. Meinardi JR, Middeldorp S, De Kam PJ, Koopman MM, Van Pampus EC, Hamulyak K et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999; 130:736-739.
38. Brenner B, Vulfsons SL, Lanir N, Nahir M: Coexistence of familial antiphospholipid syndrome and factor V Leiden: Impact on thrombotic diathesis. Br J Haematol 1996; 94:166-167.
39. Younis JS, Brenner B, Ohel G, Tal J, Lanir N, Ben Ami M: Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 43:31-35.
40. Rai R, Shlebak A, Cohen H, Backos M, Holmes Z, Marriott K et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16:961-965.
41. Bare SN, Poka R, Balogh I, Ajzner E: Factor V Leiden as a risk factor for miscarriage and reduced fertility. Aust N Z J Obstet Gynaecol 2000; 40:186-190.
42. Preston FE, Rosendaal FR, Walker ID, Briet E, Berntorp E, Conard J et al. Increased feta loss in women with heritable thrombophilia. Lancet 1996; 348:913-916.
43. Kutteh WH, Park VM, Deitcher SR: Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril 1999; 71:1048-1053.
44. Coumans AB, Huijgens PC, Jakobs C, Schats R, De Vries JI, Van Pampus MG et al. Haemostatic and metabolic abnormalities in women with unexplained recurrent abortion. Hum Reprod 1999; 14:211-214.
45. Pihusch R, Buchholz T, Lohse P, Rübsamen H, Rosenhofer N, Hasbargen U et al.: Thrombophilic gene mutations and recurrent spontaneous abortion: Prothrombin increases the risk in the first trimester. Am J Reprod Immunol 2001; 46:124-131.
46. Lindqvist PG, Svensson PJ, Dahlback B, Marsal K: Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss - A possible evolutionary selection mechanism. Thromb Haemost 1998; 79:69-73.
47. Livingston JC, Barton JR, Park V, Haddad B, Phillips O, Sibai BM: Maternal and fetal inherited thrombophilias are not related to the development of severe preeclampsia. Am J Obstet Gynecol 2001; 185:153-157.
48. Brenner B, Sarig G, Weiner Z, Younis J, Blumenfeld Z, Lanir N: Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost 1999; 82:6-9.
49. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C et al. Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis. N Engl J Med 1996; 334:763-768.
50. Brenner B: Inherited thrombophilia and fetal loss. Curr Opin Hematol 2000; 7:290-295.
51. Adamek L, Jankowski M, Sanak M, Krzanowski M, Grzanka P, Nizankowska E et al. Coincidence of 20210A prothrombin variant and factor V Leiden predisposing to venous thromboembolism. Pol Arch Med Wewn 1999; 102:1095-1099.
52. Goodwin TM: Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv 1989; 44:157-161.
53. Haverkate F, Samama M: Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73:151-161.
54. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G et al. Beta fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du Myocarde. Circulation 1996; 93:440-449.
55. Egbring R, Kroniger A, Seitz R: Factor XIII deficiency: Pathogenic mechanisms and clinical significance. Semin Thromb Hemost 1996; 22:419-425.
56. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ: Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93:906-908.
57. Franco RF, Reitsma PH, Lourenco D, Maffei FH, Morelli V, Tavella MH et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81: 676-679.
58. Anwar R, Gallivan L, Edmonds SD, Markham AF: Genotype/phenotype correlations for coagulation factor XIII: Specific normal polymorphisms are associated with high or low factor XIII specific activity. Blood 1999; 93:897-905.
59. Miloszewski K, Losowsky M: Fibrin stabilisation and factor XIII deficiency. In Francis L, editor. Fibronogen, Fibrin Stabilisation and Fibrinolysis. UK: 1988, p. 175.
60. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C: Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68:1370-1373.
61. Baker WF, Bick RL: Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 1999; 25:387-406.
62. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81:198-202.
63. Makris M, Leach M, Beauchamp NJ, Daly ME, Cooper PC, Hampton KK et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood 2000; 95:1935-1941.
64. Bertina RM, Ploos Van Amstel HK, Van Wijngaarden A, Coenen J, Leemhuis MP, Deutz-Terlouw PP et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 1990; 76:538-548.
65. Decker PJ, Scott CH, Fishman LS, Sutton MS: A rare case of coronary artery occlusion diagnosed by echocardiography. Am J Cardiol 1995; 75:104-105.
66. Egeberg O: Inherited fibrinogen abnormality causing thrombophilia. Thromb Diath Haemorrh 1967; 17:176-187.
67. Girling J, De Swiet M: Inherited thrombophilia and pregnancy. Curr Opin Obstet Gynecol 1998; 10:135-144.
68. Ishiguro K, Kojima T, Kadomatsu K, Nakayama Y, Takagi A, Suzuki M et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106:873-878.
69. Sartori MT, Wiman B, Vettore S, Dazzi F, Girolami A, Patrassi GM: 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis. Thromb Haemost 1998; 80:956-960.
70. Citarella F, Misiti S, Felici A, Aiuti A, La Porta C, Fantoni A: The 5′ sequence of human factor XII gene contains transcription regulatory elements typical of liver specific, estrogen-modulated genes. Biochim Biophys Acta 1993; 1172:197-199.
71. Citarella F, Ravon DM, Pascucci B, Felici A, Fantoni A, Hack CE: Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces. Eur J Biochem 1996; 238:240-249.
72. Wuillemin WA, Hack CE, Bleeker WK, Biemond BJ, Levi M, Ten Cate H: Inactivation of factor Xia in vivo: Studies in chimpanzees and in humans. Thromb Haemost 1996; 76:549-555.
73. Braat EA, Rijken DC: The inactivation of single-chain urokinase-type plasminogen activator by thrombin may provide an additional explanation for the antifibrinolytic effect of factor XI. Thromb Haemost 1999; 81:657.
74. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S: Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11:183-190.
75. Henry M, Chomiki N, Scarabin PY, Alessi MC, Peiretti F, Arveiler D, et al. Five frequent polymorphisms of the PAI-1 gene: Lack of association between genotypes, PAI activity, and triglyceride levels in a healthy population. Arterioscler Thromb Vasc Biol 1997; 17:851-858.
76. Grubic N, Stegnar M, Peternel P, Kaider A, Binder BR: A novel G/A and the 4G/5G polymorphism within the promoter of the plasminogen activator inhibitor-1 gene in patients with deep vein thrombosis. Thromb Res 1996; 84:431-443.
77. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10,739-10,745.
78. Kimura H, Gejyo F, Suzuki Y, Suzuki S, Miyazaki R, Arakawa M: Polymorphisms of angiotensin converting enzyme and plasminogen activator inhibitor-1 genes in diabetes and macroangiopathy 1. Kidney Int 1998; 54:1659-1669.
79. Catto AJ, Carter AM, Stickland M, Bamford JM, Davies JA, Grant PJ: Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997; 77:730-734.
80. Morange PE, Henry M, Tregouet D, Granel B, Aillaud MF, Alessi MC et al. The A-844G polymorphism in the PAI-1 gene is associated with a higher risk of venous thrombosis in factor V Leiden carriers. Arterioscler Thromb Vasc Biol 2000; 20:1387-1391.
81. Glueck CJ, Phillips H, Cameron D, Wang P, Fontaine RN, Moore SK et al. The 4G/5G polymorphism of the hypofibrinolytic plasminogen activator inhibitor type 1 gene: An independent risk factor for serious pregnancy complications. Metabolism 2000; 49:845-852.
82. Yamada N, Arinami T, Yamakawa-Kobayashi K, Watanabe H, Sohda S, Hamada H et al. The 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene is associated with severe preeclampsia. J Hum Genet 2000; 45:138-141.
83. Gris JC, Neveu S, Mares P, Biron C, Hedon B, Schved JF: Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med 1993; 122:606-615.
84. Gris JC, Ripart-Neveu S, Maugard C, Tailland ML, Brun S, Courtieu C et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians Haematologists (NOHA) Study. Thromb Haemost 1997; 77:1096-1103.
85. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51:197-205.
86. Kim DK, Kim JW, Kim S, Gwon HC, Ryu JC, Huh JE et al. Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 1997; 17:3242-3247.
87. Von Kanel R, Wuillemin WA, Furlan M, Lammle B: Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagul Fibrinolysis 1992; 3:555-561.
88. Kanaji T, Okamura T, Osaki K, Kuroiwa M, Shimoda K, Hamasaki N et al. A common genetic polymorphism (46 C to T substitution) in the 5′-untranslated region of the coagulation factor XII gene is associated with low translation efficiency and decrease in plasma factor XII level. Blood 1998; 91:2010-2014.
89. Braulke I, Pruggmayer M, Melloh P, Hinney B, Kostering H, Gunther E: Factor XII (Hageman) deficiency in women with habitual abortion: New subpopulation of recurrent aborters? Fertil Steril 1993; 59:98-101.
90. Ogasawara MS, Aoki K, Katano K, Ozaki Y, Suzumori K: Factor XII but not protein C, protein S, anti-thrombin III, or factor XIII is a predictor of recurrent miscarriage. Fertil Steril 2001; 75:916-919.
91. Yamada H, Kato EH, Ebina Y, Kishida T, Hoshi N, Kobashi G, Sakuragi N, Fujimoto S: FXII deficiency in women with recurrent miscarriage. Gynecol Obstet Invest 2000; 49:80-83.
92. Matsuura T, Kobayashi T, Asahina T, Kanayama N, Terao T: Is factor XII deficiency related to recurrent miscarriage? Semin Thromb Hemost 2001; 27:115-120.
93. Kluijtmans LA, Van Den Heuvel LP, Boers GH, Frosst P, Stevens EM, Van Oost BA et al. Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58:35-41.
94. Stampfer MJ, Willett WC: Homocysteine and marginal vitamin deficiency. The importance of adequate vitamin intake. JAMA 1993; 270:2726-2727.
95. Perry DJ: Hyperhomocysteinaemia. Baillieres Best. Pract Res Clin Haematol 1999; 12:451-477.
96. Nelen WL, Steegers EA, Eskes TK, Blom HJ: Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet 1997; 350:861.
97. Unander AM, Norberg R, Hahn L, Arfors L: Anti-cardiolipin antibodies and complement in ninety-nine women with habitual abortion. Am J Obstet Gynecol 1987; 156:114-119.
98. Sohda S, Arinami T, Hamada H, Yamada N, Hamaguchi H, Kubo T: Methylenetetrahydrofolate reductase polymorphism and pre-eclampsia. J Med Genet 1997; 34:525-526.
99. Powers RW, Minich LA, Lykins DL, Ness RB, Crombleholme WR, Roberts JM: Methylenetetrahydrofolate reducase polymorphism, folate, and susceptibility to preeclampsia. J Soc Gynecol Invest 1999; 6:74-79.
100. Gaustadnes M, Rudiger N, Rasmussen K, Ingerslev J: Intermediate and severe hyperhomocysteinemia with thrombosis: A study of genetic determinants. Thromb Haemost 2000; 83:554-558.
101. Hasbargen U, Lohse P, Thaler CJ: The number of dichorionic twin pregnancies is reduced by the common MTHFR 677C->T mutation. Hum Reprod 2000; 15:2659-2662.
102. Mathews F, Murphy M, Wald NJ, Hackshaw A: Twinning and folic acid use. Lancet 1999; 353:291-292.
103. Bonnar J: Can more be done in obstetric and gynecologic practice to reduce morbidity and mortality associated with venous thromboembolism? Am J Obstet Gynecol 1999; 180:784-791.
104. Gerhardt A, Scharf RE, Beckmann MW, Struve S, Bender HG, Pillny M et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374-380.
105. Khong TY, Hague WM: Biparental contribution to fetal thrombophilia in discordant twin intrauterine growth restriction. Am J Obstet Gynecol 2001; 185:244-245.